^
    Apply
    Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer (NCT02600949)
    Phase 1
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    06/12/2024
    Initiation :
    05/11/2016
    Primary completion :
    05/31/2025
    Completion :
    05/31/2025
    CEACAM5
    |
    Keytruda (pembrolizumab) • Zyclara (imiquimod) • sotigalimab (PYX-107)
    Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod (NCT00799110)
    Phase 2
    Beth Israel Deaconess Medical Center
    Active, not recruiting
    Last update posted :
    06/11/2024
    Initiation :
    08/01/2008
    Primary completion :
    12/01/2024
    Completion :
    12/01/2024
    CSF2
    |
    Zyclara (imiquimod)
    A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas (INTERCEPT-H3) (NCT04808245)
    Phase 1
    German Cancer Research Center
    Recruiting
    Last update posted :
    04/05/2024
    Initiation :
    02/15/2023
    Primary completion :
    03/01/2025
    Completion :
    03/01/2025
    IFNG
    |
    H3.3K27M
    |
    Tecentriq (atezolizumab) • Zyclara (imiquimod)
    Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides (NCT05838599)
    Phase 1
    Northwestern University
    Recruiting
    Last update posted :
    03/11/2024
    Initiation :
    07/24/2023
    Primary completion :
    08/01/2025
    Completion :
    02/01/2026
    CD4
    |
    Zyclara (imiquimod)
    Patient-individualized Peptide Vaccination Based on Tumor-specific Mutations in Children and Young Adults With Primary/Relapsed ALL (NCT03559413)
    Phase 1/2
    University Children's Hospital Tuebingen
    Completed
    Last update posted :
    12/04/2023
    Initiation :
    06/01/2016
    Primary completion :
    03/01/2022
    Completion :
    12/01/2023
    CD8 • CD4
    |
    CD8 expression • CD4 expression
    |
    Zyclara (imiquimod)
    Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors (AM-003) (NCT04116320)
    Phase 1
    Craig L Slingluff, Jr
    Active, not recruiting
    Last update posted :
    08/07/2023
    Initiation :
    11/21/2019
    Primary completion :
    02/01/2024
    Completion :
    02/01/2024
    PD-L1
    |
    Zyclara (imiquimod) • Hiltonol (poly-ICLC)
    NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting) (NCT00142454)
    Phase 1
    Ludwig Institute for Cancer Research
    Completed
    Last update posted :
    10/10/2022
    Initiation :
    08/24/2005
    Primary completion :
    04/25/2006
    Completion :
    04/25/2006
    CTAG1B • CD4
    |
    Zyclara (imiquimod)
    HER2-Peptide Vaccination of Patients With Solid Tumors (NCT02276300)
    Phase 1
    Technische Universität München
    Completed
    Last update posted :
    11/20/2019
    Initiation :
    12/01/2014
    Primary completion :
    07/18/2017
    Completion :
    07/13/2018
    HER-2
    |
    cyclophosphamide • Zyclara (imiquimod) • Leukine (sargramostim) • cyclophosphamide intravenous
    Pilot Study of DRibble Vaccine for Prostate Cancer Patients (NCT02234921)
    Phase 1
    UbiVac
    Completed
    Last update posted :
    10/11/2018
    Initiation :
    10/24/2014
    Primary completion :
    08/15/2018
    Completion :
    08/15/2018
    AR
    |
    cyclophosphamide • Zyclara (imiquimod) • DPV-001 • cyclophosphamide intravenous
    Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer (NCT00821964)
    Phase 2
    University of Washington
    Completed
    Last update posted :
    01/02/2018
    Initiation :
    12/01/2008
    Primary completion :
    11/01/2012
    Completion :
    11/29/2012
    HER-2 • IFNG • TGFB1 • IGFBP2
    |
    albumin-bound paclitaxel • Zyclara (imiquimod)
    Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy (NCT02452307)
    Phase 1/2
    University Hospital Tuebingen
    Unknown status
    Last update posted :
    08/17/2017
    Initiation :
    04/01/2004
    Primary completion :
    10/01/2017
    Completion :
    10/01/2017
    HLA-A
    |
    HLA-A*02 • HLA-A2 positive
    |
    Zyclara (imiquimod)
    Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1 (NCT00865644)
    Phase 1
    Massachusetts General Hospital
    Completed
    Last update posted :
    01/10/2017
    Initiation :
    03/01/2009
    Primary completion :
    04/01/2010
    Completion :
    12/01/2013
    NF1
    |
    Zyclara (imiquimod)